DOCSLIB.ORG

ABSTRACT the Importance of Cathepsin B Research and Clinical

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ABSTRACT the Importance of Cathepsin B Research and Clinical ABSTRACT The Importance of Cathepsin B Research and Clinical Applications David M. Kosa Director: Amanda C. Sevcik, Ph.D. Cathepsin B is a cysteine protease of the papain family. It plays an important role in intracellular proteolysis, but it displays exopeptidase activity due to a unique structural element called the occluding loop. There is also a large amount of evidence that cathepsin B is involved in the development and progression of cancer, Alzheimer’s disease, and pathological conditions. Throughout this thesis cathepsin B is analyzed for its role in pathology, enzyme mechanisms, and protease activity. APPROVED BY DIRECTOR OF HONORS THESIS: _________________________________________________ Dr. Amanda Sevcik APPROVED BY THE HONORS PROGRAM: _______________________________________________ Dr. Elizabeth Corey, Director DATE: __________________________ THE IMPORTANCE OF CATHEPSIN B RESEARCH AND CLINICAL APPLICATIONS A Thesis Submitted to the Faculty of Baylor University In Partial Fulfillment of the Requirements for the Honors Program By David M. Kosa Waco, Texas May 2020 TABLE OF CONTENTS LIST OF FIGURES . iii LIST OF TABLES . iv DEDICATION . v CHAPTER ONE – Foundation of Cathepsin B Research . 1 CHAPTER TWO – Enzymology of Cathepsin B . 5 CHAPTER THREE – Inhibitors . 17 CHAPTER FOUR – Proposed Mechanisms in Medical Research . 23 CHAPTER FIVE – Concluding Words . 28 BIBLIOGRAPHY . 29 ii LIST OF FIGURES FIGURE 1 . 5 FIGURE 2 . 7 FIGURE 3 . 9 FIGURE 4 . 10 FIGURE 5 . 11 FIGURE 6 . 13 FIGURE 7 . 15 FIGURE 8 . 17 FIGURE 9 . 22 FIGURE 10 . 24 FIGURE 11 . 25 iii LIST OF TABLES TABLE 1 . 8 iv DEDICATION To my loving family, my dear friends, my Thesis Director Dr. Sevcik, and the dedicated professors of the Baylor science departments. v CHAPTER ONE Foundation of Cathepsin B Research Introduction to Cathepsin B The lysosomal cysteine protease, cathepsin B, plays a valuable role in proteolysis, the breakdown of proteins into smaller components for recycling and cellular housekeeping. Cathepsin B “is of significant importance to cancer therapy as it is involved in various pathologies and oncogenic processes in humans.”1 However, the specificity of the compound, and the complex role of cathepsin B in cancer treatment has hampered the advancement of clinical application.2 Although researchers have spent decades studying cathepsin B, little is actually known about the mechanisms of it in regards to activation, regulation, and inhibition. Despite the lack of information, scientists have pursued research of cathepsin B in hopes of producing notable work in the field of cancer and disease treatment. Historical Importance of Current Research Cathepsin B has been the focus of numerous researchers and experiments since the late 1900’s. The first known documented report on cathepsin B is in 1957 by Greenbaum and Fruton.3 Although they were only studying the purification and properties of the compound, their work began the cascade that would become crucial to the human understanding of proteases. Shortly afterwards, Greenbaum joined with Schoichet and Hirshkowitz to analyze the activation process of trypsinogen by cathepsin B.4 A few other scientists joined in the initial research on the protease in hopes of 1 understanding the methods of activation; however, cathepsin B was mostly unknown during the 1950’s. The experiments in the early 1900’s were focused on the effects of cathepsins as a whole with the occasional reference to a distinct “cathepsin C” in some articles with Fruton as a primary researcher. The 1952 article “On the proteolytic enzymes of animal tissues. Beef spleen cathepsin C” was the first article to mention a clearly distinguished compound known as cathepsin C.5 The second article on distinguished cathepsins was focused on the transamidation reactions that are catalyzed by cathepsin C.6 It was not until around the late 1970’s that cathepsin B became popularized across research groups and experiments. Part of this increase in popularity can be attributed to the Barrett assay of cathepsin B which was improved in 1976.7 The assay ultimately utilized the cleavage of the substrate benzyoyl-DL-arginine 2- napthylamide and the coupling of a diazonium salt with a napthylamine to generate a compound capable of being read at an absorbance of A520 nm. With new techniques being developed, the number of articles being written on cathepsin B rapidly began to increase until researchers began to realize that the inhibition of cathepsin B could be crucial in preventing cancerous growth because of its role as an extracellular membrane degrader. The first inhibitor of cathepsin B, haptoglobin, was found by Snellmann and Sylvén; it is natural inhibitor of cathepsin B activity where haptoglobin is a protein that is responsible for binding to free hemoglobin in circulation. However, it was not until the German scientists Appel, Huth, and Herrmann discovered the implications of cathepsin overexpression, that scientists began to realize that inhibition of cathepsin B could be a viable strategy for treating a variety of diseases and cancers. Appel et al.’s experiment involved the serum testing of 43 children with varying 2 alterations of health. Of the children with inflammatory diseases, specifically leukemia and pneumonia, most of them experienced an increase in a variety of protein compounds including cathepsin B and cathepsin C. Recent research with cathepsin B has provided a solid framework and guideline for future experimentation in the clinical field. Notably, the acceptance of cathepsin B being regarded as an effective biomarker for a plethora of cancers has pushed research advancement towards clinical experimentation.8–13 Research on cathepsin B involvement in cancer may be the most common, but there is almost an equivalent amount of evidence that it is involved in a wide variety of diseases and conditions. Given that cathepsin B is capable of crossing the blood-brain barrier and is involved in numerous pathological processes like inflammation, cell death, and the production of toxic peptides, it is highly influential in neurological diseases.14 Specifically in reference to neurological diseases, cathepsin B can be tied to epilepsy caused by apoptotic cell death, inhibitor treatments to prevent the decay of brain neurons and inflammation, and amyloid plaque production in Alzheimer’s disease.15–17 With such an extensive repertoire of clinical implications, cathpesin B is definitely a highly valued research target and the focus of numerous experimentations. Purpose of this Thesis Overall, the majority of the early research on cathepsin B was severely limited by the lack of information on the structure, composition, and specificity of the cysteine protease. However, this limitation was overcome as technological advances and interest grew. Eventually, the mechanistic models of cathepsin B began to advance as more information on the protein became available. Although the mechanistic models have 3 improved, the current understanding of cathepsin B is still limited. Because cathepsin B is highly involved in the clinical research of cancer and neurodegenerative diseases, there are increasingly more research groups and individuals wanting to learn about cathepsin B and the best methods to manipulate the mechanism of action in favor of inhibition. However, the complexity of cathepsin B has left significant gaps in the development of understanding cathepsin B. These gaps allow room for contradictory theories, and confusion in understanding the mechanisms of cathepsin B activity and regulation. The purpose of this thesis is to detail the comprehensive progress in the enzymology of cathepsin B while approaching theories and intricate mechanisms in order to show the potential of cathepsin B research and its clinical application. 4 CHAPTER TWO Enzymology of Cathepsin B Structure Because cathepsin B undergoes “considerable variation in its posttranslational modification,” it has been difficult to identify its numerous roles in “physiological and pathological processes.”18 The complete protein sequence was largely unknown until 1983 when Takio et al. published their work on rat liver enzymes.19 Today, it is known that the cathepsin B gene is located on chromosome 8, and it can be identified as the CTSB Gene. The location of the gene can be found below in Figure 1. Figure 1. Showing the Genomic Location of CTSB Gene in Chromosome 8. The red line located between p23 and p22 shows the location of the CTSB Gene. The exact location is marked as 8p23.1 20 In 1991, Musil et al. were finally able to decipher the crystal structure of human liver cathepsin B through Patterson search and heavy atom replacement methods. The Patterson function is equivalent to the Fourier transform of the intensities of the compound rather than the structure. The Patterson function was used in this approach because it is useful in solving the phase problem in X-ray crystallography. Shortly thereafter in 1996, Cygler et al. synthesized the inactive precursor of cathepsin B, procathepsin B. Both of these breakthroughs were pivotal in developing the fundamental 5 basis of cathepsin B specificity. Because of the X-ray data, Musil et al. were able to reconfirm the disulfide connectivities of bovine cathepsin B that were proven chemically correct by Bettie Evans and Elliott Shaw.21 Overall, Cathepsin B is a bilobal protein of approximately 30kDa with the active site and the substrate binding site located between two large lobes of the protein.22 The precursor, procathepsin B consists of 43~46 kDa. When the mature cathepsin B is formed, the procathepsin B is split apart into two chains linked together by a disulfide bridge. The heavy chain of cathepsin B is approximately 25 to 26 kDa, and the light chain is approximately 5 kDa.20 The enzyme is synthesized as a preproenzyme of 339 amino acids, and it has a signal peptide consisting of 17 amino acids. When matured and modified, human liver cathepsin B is reduced to a sequence length of 205 amino acids on the heavy chain and 47 amino acids on the light chain.23 Musil et al.
Load more

Recommended publications
  • Cathepsin B-Independent Abrogation of Cell Death by CA-074-Ome Upstream of Lysosomal Breakdown
    Cell Death and Differentiation (2004) 11, 1357–1360 & 2004 Nature Publishing Group All rights reserved 1350-9047/04 $30.00 www.nature.com/cdd Letter to the Editor Cathepsin B-independent abrogation of cell death by CA-074-OMe upstream of lysosomal breakdown Cell Death and Differentiation (2004) 11, 1357–1360. doi:10.1038/sj.cdd.4401493 Published online 6 August 2004 Dear Editor, Recent progress provided compelling evidence for the major cence microscope observation (not shown). Overall cell death role of lysosomal cathepsin proteases in cell death pathways (apoptosis þ necrosis) was also significantly diminished by especially when caspase activity is suppressed.1,2 Cathepsin the caspase inhibitor (Po0,05), but without major effect B, a ubiquitous endopeptidase and ectodipeptidase, was (mean percentage of cell death for staurosporine: 92.1; for shown to be a component of TNF-a cell death signaling,3 as staurosporine þ Z-VAD(OMe)-FMK: 62.3; n ¼ 7) (Figure 1f). well as an executor protease in caspase-compromised cells To explore if various cellular compartments are involved in induced to undergo apoptosis4 or necrosis.5 DEVD-ase-independent cell death, acidity of endolysosomes L-trans-epoxysuccinyl-Ile-Pro-OH propylamide (CA-074) is and the inner membrane potential of mitochondria were a highly specific inhibitor of cathepsin B.6 The methylated measured by appropriate fluorescent dyes and flow cytometry variant, CA-074-OMe, was shown to penetrate into cells more (Figure 1b–e). A remarkable decline of acidic compartments easily than the parental molecule,7 whereas it loosened its was detected by acridine orange in the major population of cathepsin B specificity reacting with other, unidentified staurosporine þ Z-VAD(OMe)-FMK-treated cells (Figure 1b).
    [Show full text]
  • P53 and the Cathepsin Proteases As Co-Regulators of Cancer and Apoptosis
    cancers Review Making Connections: p53 and the Cathepsin Proteases as Co-Regulators of Cancer and Apoptosis Surinder M. Soond 1,*, Lyudmila V. Savvateeva 1, Vladimir A. Makarov 1, Neonila V. Gorokhovets 1, Paul A. Townsend 2 and Andrey A. Zamyatnin, Jr. 1,3,4,* 1 Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Trubetskaya Str. 8-2, 119991 Moscow, Russia; [email protected] (L.V.S.); [email protected] (V.A.M.); gorokhovets_n_v@staff.sechenov.ru (N.V.G.) 2 Division of Cancer Sciences and Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, and the NIHR Manchester Biomedical Research Centre, Manchester M13 9PL, UK; [email protected] 3 Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia 4 Department of Biotechnology, Sirius University of Science and Technology, 1 Olympic Ave, 354340 Sochi, Russia * Correspondence: [email protected] (S.M.S.); [email protected] (A.A.Z.J.) Received: 6 October 2020; Accepted: 19 November 2020; Published: 22 November 2020 Simple Summary: This article describes an emerging area of significant interest in cancer and cell death and the relationships shared by these through the p53 and cathepsin proteins. While it has been demonstrated that the p53 protein can directly induce the leakage of cathepsin proteases from the lysosome, directly triggering cell death, little is known about what factors set the threshold at which the lysosome can become permeabilized. It appears that the expression levels of cathepsin proteases may be central to this process, with some of them being transcriptionally regulated by p53.
    [Show full text]
  • Cathepsins and Their Involvement in Immune Responses
    Review article: Medical intelligence | Published 20 July 2010, doi:10.4414/smw.2010.13042 Cite this as: Swiss Med Wkly. 2010;140:w13042 Cathepsins and their involvement in immune responses Sébastien Conus, Hans-Uwe Simon Institute of Pharmacology, University of Bern, Bern, Switzerland Correspondence to: cleaving proteases (= caspases) which cleave a wide range Sébastien Conus Ph.D. of cellular substrates [5]. Institute of Pharmacology Besides caspases, cathepsins have recently been shown University of Bern to be associated with cell death regulation [6–12] and vari- Friedbühlstrasse 49 3010 Bern ous other physiological and pathological processes, such as Switzerland maturation of the MHC class II complex, bone remodel- [email protected] ling, keratinocyte differentiation, tumour progression and metastasis, rheumatoid arthritis and osteoarthritis, as well Summary as atherosclerosis [13, 14] (table 1). Thus, cathepsins ap- pear to play a significant role in immune responses. In this The immune system is composed of an enormous variety of review we discuss recent advances addressing the role of cells and molecules that generate a collective and coordin- lysosomal proteases in the diverse aspects of the immune ated response on exposure to foreign antigens, called the response, and also the involvement of cathepsins in the immune response. Within the immune response, endo-lyso- pathogenesis of diseases in which these proteases seem not somal proteases play a key role. In this review we cover to be properly under control. specific roles of cathepsins in innate and adaptive immu- nity, as well as their implication in the pathogenesis of sev- The cathepsin family eral diseases. Lysosomes are membrane-bound organelles which repres- Key words: adaptive and innate immunity; apoptosis; ent the main degradative compartment in eukaryotic cells.
    [Show full text]
  • A Cysteine Protease Inhibitor Blocks SARS-Cov-2 Infection of Human and Monkey Cells
    bioRxiv preprint doi: https://doi.org/10.1101/2020.10.23.347534; this version posted October 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells Drake M. Mellott,1 Chien-Te Tseng,3 Aleksandra Drelich,3 Pavla Fajtová,4,5 Bala C. Chenna,1 Demetrios H. Kostomiris1, Jason Hsu,3 Jiyun Zhu,1 Zane W. Taylor,2,9 Vivian Tat,3 Ardala Katzfuss,1 Linfeng Li,1 Miriam A. Giardini,4 Danielle Skinner,4 Ken Hirata,4 Sungjun Beck4, Aaron F. Carlin,8 Alex E. Clark4, Laura Beretta4, Daniel Maneval6, Felix Frueh,6 Brett L. Hurst,7 Hong Wang,7 Klaudia I. Kocurek,2 Frank M. Raushel,2 Anthony J. O’Donoghue,4 Jair Lage de Siqueira-Neto,4 Thomas D. Meek1.*, and James H. McKerrow#4,* Departments of Biochemistry and Biophysics1 and Chemistry,2 Texas A&M University, 301 Old Main Drive, College Station, Texas 77843, 3Department of Microbiology and Immunology, University of Texas, Medical Branch, 3000 University Boulevard, Galveston, Texas, 77755-1001, 4Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, 5Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 16610 Prague, Czech Republic, 6Selva Therapeutics, and 7Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, 5600 Old Main Hill, Utah State University, Logan, Utah, 84322, 8Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA 92037, USA.9Current address: Biological Sciences Division, Pacific Northwest National Laboratory, 902 Battelle Blvd, Richland, WA 99353.
    [Show full text]
  • Cysteine Cathepsin Proteases: Regulators of Cancer Progression and Therapeutic Response
    REVIEWS Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response Oakley C. Olson1,2 and Johanna A. Joyce1,3,4 Abstract | Cysteine cathepsin protease activity is frequently dysregulated in the context of neoplastic transformation. Increased activity and aberrant localization of proteases within the tumour microenvironment have a potent role in driving cancer progression, proliferation, invasion and metastasis. Recent studies have also uncovered functions for cathepsins in the suppression of the response to therapeutic intervention in various malignancies. However, cathepsins can be either tumour promoting or tumour suppressive depending on the context, which emphasizes the importance of rigorous in vivo analyses to ascertain function. Here, we review the basic research and clinical findings that underlie the roles of cathepsins in cancer, and provide a roadmap for the rational integration of cathepsin-targeting agents into clinical treatment. Extracellular matrix Our contemporary understanding of cysteine cathepsin tissue homeostasis. In fact, aberrant cathepsin activity (ECM). The ECM represents the proteases originates with their canonical role as degrada- is not unique to cancer and contributes to many disease multitude of proteins and tive enzymes of the lysosome. This view has expanded states — for example, osteoporosis and arthritis4, neuro­ macromolecules secreted by considerably over decades of research, both through an degenerative diseases5, cardiovascular disease6, obe- cells into the extracellular
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • The P53-Cathepsin Axis Cooperates with ROS to Activate Programmed Necrotic Death Upon DNA Damage
    The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death upon DNA damage Ho-Chou Tua,1, Decheng Rena,1, Gary X. Wanga, David Y. Chena, Todd D. Westergarda, Hyungjin Kima, Satoru Sasagawaa, James J.-D. Hsieha,b, and Emily H.-Y. Chenga,b,c,2 aDepartment of Medicine, Molecular Oncology, bSiteman Cancer Center, and cDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110 Edited by Stuart A. Kornfeld, Washington University School of Medicine, St. Louis, MO, and approved November 25, 2008 (received for review August 19, 2008) Three forms of cell death have been described: apoptosis, autophagic cells that are deprived of the apoptotic gateway to mediate cyto- cell death, and necrosis. Although genetic and biochemical studies chrome c release for caspase activation (Fig. S1) (9–11, 19, 20). have formulated a detailed blueprint concerning the apoptotic net- Despite the lack of caspase activation (20), DKO cells eventually work, necrosis is generally perceived as a passive cellular demise succumb to various death signals manifesting a much slower death resulted from unmanageable physical damages. Here, we conclude an kinetics compared with wild-type cells (Fig. 1A, Fig. S2, and data active de novo genetic program underlying DNA damage-induced not shown). To investigate the mechanism(s) underlying BAX/ necrosis, thus assigning necrotic cell death as a form of ‘‘programmed BAK-independent cell death, we first examined the morphological cell death.’’ Cells deficient of the essential mitochondrial apoptotic features of the dying DKO cells. Electron microscopy uncovered effectors, BAX and BAK, ultimately succumbed to DNA damage, signature characteristics of necrosis in DKO cells after DNA exhibiting signature necrotic characteristics.
    [Show full text]
  • Kinetic Properties and Characterization of Purified Proteases from Pacific Whiting
    AN ABSTRACT OF THE THESIS OF JuWen Wu for the degree of Master of Science in Food Science and Technology presented on March 10. 1994 . Title: Kinetic Properties and Characterization of Purified Proteases from Pacific Whiting (Merluccius productus) . Abstract approved: ._ ■^^HaejWg An Kinetic properties of the two proteases, causing textural degradation of Pacific whiting (Merluccius productus) during heating, were compared and characterized with the synthetic substrate, Z-Phe-Arg-NMec. Pacific whiting P-I and P-II showed the highest specificity on Z-Phe-Arg-NMec, specific substrate for cathepsin L. The Km of 1 preactivated P-I and P-II were 62.98 and 76.02 (^M), and kcat, 2.38 and 1.34 (s" ) against Z-Phe-Arg-NMec at pH 7.0 and 30°C, respectively. Optimum pH stability for preactivated P-I and P-II is between 4.5 and 5.5. Both enzymes showed similar pH- induced preactivation profiles at 30oC. The maximal activity for both enzymes was obtained by preactivating the enzyme at a range of pH 5.5 to 7.5. The highest activation rate for both enzymes was determined at pH 7.5. At pH 5.5, the rate to reach the maximal activity was the slowest, but the activity was stable up to 1 hr. P-I and P-II shared similar temperature profiles at pH 5.5 and pH 7.0 studied. Optimum temperatures at pH 5.5 and 7.0 for both proteases on the same substrate were 550C. Significant thermal inactivation for both enzymes was shown at 750C.
    [Show full text]
  • A Rationale for Targeting Sentinel Innate Immune Signaling of Group 1 House Dust Mite Allergens Th
    Molecular Pharmacology Fast Forward. Published on July 5, 2018 as DOI: 10.1124/mol.118.112730 This article has not been copyedited and formatted. The final version may differ from this version. MOL #112730 1 Title Page MiniReview for Molecular Pharmacology Allergen Delivery Inhibitors: A Rationale for Targeting Sentinel Innate Immune Signaling of Group 1 House Dust Mite Allergens Through Structure-Based Protease Inhibitor Design Downloaded from molpharm.aspetjournals.org Jihui Zhang, Jie Chen, Gary K Newton, Trevor R Perrior, Clive Robinson at ASPET Journals on September 26, 2021 Institute for Infection and Immunity, St George’s, University of London, Cranmer Terrace, London SW17 0RE, United Kingdom (JZ, JC, CR) State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, P.R. China (JZ) Domainex Ltd, Chesterford Research Park, Little Chesterford, Saffron Walden, CB10 1XL, United Kingdom (GKN, TRP) Molecular Pharmacology Fast Forward. Published on July 5, 2018 as DOI: 10.1124/mol.118.112730 This article has not been copyedited and formatted. The final version may differ from this version. MOL #112730 2 Running Title Page Running Title: Allergen Delivery Inhibitors Correspondence: Professor Clive Robinson, Institute for Infection and Immunity, St George’s, University of London, SW17 0RE, UK [email protected] Downloaded from Number of pages: 68 (including references, tables and figures)(word count = 19,752) 26 (main text)(word count = 10,945) Number of Tables: 3 molpharm.aspetjournals.org
    [Show full text]
  • VEGF-A Induces Angiogenesis by Perturbing the Cathepsin-Cysteine
    Published OnlineFirst May 12, 2009; DOI: 10.1158/0008-5472.CAN-08-4539 Published Online First on May 12, 2009 as 10.1158/0008-5472.CAN-08-4539 Research Article VEGF-A Induces Angiogenesis by Perturbing the Cathepsin-Cysteine Protease Inhibitor Balance in Venules, Causing Basement Membrane Degradation and Mother Vessel Formation Sung-Hee Chang,1 Keizo Kanasaki,2 Vasilena Gocheva,4 Galia Blum,5 Jay Harper,3 Marsha A. Moses,3 Shou-Ching Shih,1 Janice A. Nagy,1 Johanna Joyce,4 Matthew Bogyo,5 Raghu Kalluri,2 and Harold F. Dvorak1 Departments of 1Pathology and 2Medicine, and the Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, and 3Departments of Surgery, Children’s Hospital and Harvard Medical School, Boston, Massachusetts; 4Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 5Department of Pathology, Stanford University, Stanford, California Abstract to form in many transplantable mouse tumor models are mother Tumors initiate angiogenesis primarily by secreting vascular vessels (MV), a blood vessel type that is also common in many endothelial growth factor (VEGF-A164). The first new vessels autochthonous human tumors (2, 3, 6–8). MV are greatly enlarged, to form are greatly enlarged, pericyte-poor sinusoids, called thin-walled, hyperpermeable, pericyte-depleted sinusoids that form mother vessels (MV), that originate from preexisting venules. from preexisting venules. The dramatic enlargement of venules We postulated that the venular enlargement necessary to form leading to MV formation would seem to require proteolytic MV would require a selective degradation of their basement degradation of their basement membranes.
    [Show full text]
  • Does the Use of Protease Inhibitors Further Improve in Vivo Distribution?
    Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog 177Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution? Alexander W. Sauter*1,2, Rosalba Mansi*3, Ulrich Hassiepen4, Lionel Muller4, Tania Panigada4, Stefan Wiehr2, Anna-Maria Wild2, Susanne Geistlich5, Martin B´eh´e5, Christof Rottenburger1, Damian Wild1, and Melpomeni Fani3 1Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland; 2Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tuebingen, Germany; 3Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland; 4Novartis Pharma AG, Institutes for Biomedical Research, Novartis Campus, Basel, Switzerland; and 5Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen, Switzerland performance of 177Lu-DOTA-MG11 in the presence of inhibitors. The Patients with metastatic medullary thyroid cancer (MTC) have limited human application of single compounds without unessential additives systemic treatment options. The use of radiolabeled gastrin analogs is preferable. Preliminary clinical data spotlight the stomach as a po- targeting the cholecystokinin-2 receptor (CCK2R) is an attractive tential dose-limiting organ besides the kidneys. approach. However, their therapeutic efficacy is presumably decreased Key Words: medullary thyroid cancer; cholecystokinin-2 receptor; by their enzymatic degradation in vivo. We aimed to investigate whether gastrin; peptide receptor radionuclide therapy; 177Lu-DOTA-PP-F11N 177 177 the chemically stabilized analog Lu-DOTA-PP-F11N ( Lu-DOTA- J Nucl Med 2019; 60:393–399 (DGlu)6-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2) performs better than refer- DOI: 10.2967/jnumed.118.207845 ence analogs with varying in vivo stability, namely 177Lu-DOTA-MG11 177 177 ( Lu-DOTA-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2)and Lu-DOTA- 177 PP-F11 ( Lu-DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2), and whether the use of protease inhibitors further improves CCKR2 targeting.
    [Show full text]
  • Chapter 11 Cysteine Proteases
    CHAPTER 11 CYSTEINE PROTEASES ZBIGNIEW GRZONKA, FRANCISZEK KASPRZYKOWSKI AND WIESŁAW WICZK∗ Faculty of Chemistry, University of Gdansk,´ Poland ∗[email protected] 1. INTRODUCTION Cysteine proteases (CPs) are present in all living organisms. More than twenty families of cysteine proteases have been described (Barrett, 1994) many of which (e.g. papain, bromelain, ficain , animal cathepsins) are of industrial impor- tance. Recently, cysteine proteases, in particular lysosomal cathepsins, have attracted the interest of the pharmaceutical industry (Leung-Toung et al., 2002). Cathepsins are promising drug targets for many diseases such as osteoporosis, rheumatoid arthritis, arteriosclerosis, cancer, and inflammatory and autoimmune diseases. Caspases, another group of CPs, are important elements of the apoptotic machinery that regulates programmed cell death (Denault and Salvesen, 2002). Comprehensive information on CPs can be found in many excellent books and reviews (Barrett et al., 1998; Bordusa, 2002; Drauz and Waldmann, 2002; Lecaille et al., 2002; McGrath, 1999; Otto and Schirmeister, 1997). 2. STRUCTURE AND FUNCTION 2.1. Classification and Evolution Cysteine proteases (EC.3.4.22) are proteins of molecular mass about 21-30 kDa. They catalyse the hydrolysis of peptide, amide, ester, thiol ester and thiono ester bonds. The CP family can be subdivided into exopeptidases (e.g. cathepsin X, carboxypeptidase B) and endopeptidases (papain, bromelain, ficain, cathepsins). Exopeptidases cleave the peptide bond proximal to the amino or carboxy termini of the substrate, whereas endopeptidases cleave peptide bonds distant from the N- or C-termini. Cysteine proteases are divided into five clans: CA (papain-like enzymes), 181 J. Polaina and A.P. MacCabe (eds.), Industrial Enzymes, 181–195.
    [Show full text]